18F-AV1451 uptake can more accurately predict cognition decline and neurodegeneration in AD than CSF p-tau [153], while another study found CSF p-tau elevation preceding 18F-AV1451 positivity during cognition decline [155]. Here, MAPT is linked to Alzheimer disease.